An experimental drug that attacks cancer in an entirely new way has shown promise in treating advanced melanoma, delaying progression of the disease and prolonging the lives of patients.
In clinical research, patients with advanced non-small cell lung cancer (NSCLC) that are classified as having a non-squamous histology achieve statistically significant higher survival when treated in the second-line setting with ALIMTA® (pemetrexed for injection) when compared to histologically-similar patients treated with docetaxel.
Researchers at the Centre for Addiction and Mental Health (CAMH) have clarified the link between alcohol consumption and the risk of head and neck cancers, showing that people who stop drinking can significantly reduce their cancer risk.
A new drug has shown promise in patients with advanced kidney cancer whose options run out after their tumour fails to respond to the cutting edge therapy.
Because racial or ethnic differences in response to antihypertensive drug therapies may contribute to disparities in cardiovascular disease, this systematic review of 28 studies attempts to (1) identify racial differences in the efficacy of antihypertensive drug therapies and (2) quantify the number and proportion of racial and ethnic minorities participating in these clinical trials.
An alternative design for phase II cancer clinical trials may improve success rates for new cancer drugs in phase III trials.
The difficulty in penetrating tumors and reaching all of the cancer cells is an important but under-appreciated cause of drug resistance in solid tumors, according to a review article.
The European Commission has approved Exelon® patch (rivastigmine transdermal patch), an innovative way to deliver this effective medicine to patients suffering from mild to moderately severe Alzheimer’s disease.
GlaxoSmithKline (NYSE: GSK) announced that the U.S. Food and Drug Administration (FDA) has issued an approvable letter for the new drug application (NDA) for Lamictal®XR™ (lamotrigine) Extended-Release Tablets.
Massachusetts General Hospital (MGH) researchers have a developed a totally new approach to treating liver failure – manipulating the immune response. If the results of the animal study can be applied in human patients, the approach may be able to keep patients alive until donor organs become available or to support liver function until the organ can regenerate itself, eliminating the need for a transplant.